---
title: "Influenza vaccine reduces mortality and ICU use among Brazilian SARI inpatients, 2023–2025"
id: "medrxiv-14-protective-effect-of-influenza-vaccine-in-brazilian-patients-hospitalised-for"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-14-protective-effect-of-influenza-vaccine-in-brazilian-patients-hospitalised-for"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.15.26362995v1?rss=1"
published_at: "2026-09-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Influenza vaccine reduces mortality and ICU use among Brazilian SARI inpatients, 2023–2025
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-14-protective-effect-of-influenza-vaccine-in-brazilian-patients-hospitalised-for
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.15.26362995v1?rss=1)
- **Published At:** 2026-09-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study analyzed secondary surveillance data (January 2003–October 2025) on Brazilian patients hospitalised with **severe acute respiratory infection (SARI)** to assess the association between the number of trivalent **influenza vaccine** doses received in a calendar year and hospital outcomes. - Primary exposure: number of trivalent influenza vaccine doses received in the calendar year. Key outcomes: **in-hospital mortality**, length of stay, use of the **intensive care unit (ICU)**, and ICU length of stay. - Data were analysed using **Poisson regression**; the data source cited was OpenDataSUS (SRAG dataset for 2021–2024) and additional years up to October 2025. - Influenza vaccine uptake among SARI-hospitalised patients declined from about 70% in 2023 to approximately 40–50% in 2024 and 2025. - Receiving a single vaccine dose in the year was associated with a modest reduction in measured outcomes (about 10–13%) compared with unvaccinated patients. - Receiving two influenza vaccine doses in the same calendar year was associated with larger reductions: **32% lower in-hospital mortality**, **52% fewer ICU admissions**, and **28% shorter ICU stay** compared with unvaccinated patients. - Authors conclude that two doses were moderately effective at reducing in-hospital mortality and length of stay among influenza-related SARI inpatients and suggest including 50–59-year-olds in a priority vaccination group could reduce adverse outcomes. - The report is a medRxiv preprint and has not been peer reviewed; the authors declare no competing interests. Specifics such as sample sizes, confidence intervals, and p-values were not reported in the abstract and are not available in the provided source text.
## Clinical Analysis & Structured Key Points
Protective effect of influenza vaccine in Brazilian patients hospitalised for severe acute respiratory infection, 2023-2025 | medRxiv Skip to main content Protective effect of influenza vaccine in Brazilian patients hospitalised for severe acute respiratory infection, 2023-2025 View ORCID Profile Emil Kupek doi: https://doi.org/10.64898/2026.09.15.26362995 Emil Kupek Universidade Federal de Santa Catarina, Brazil Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Emil Kupek For correspondence: emil.kupek{at}ufsc.br Abstract Info/History Metrics Data/Code Preview PDF Abstract Introduction: Despite a significant increase in influenza burden in Brazil in 2025, the associated vaccine effectiveness has not included the key end-of-winter period. Methods: The number of trivalent influenza vaccine doses received within a calendar year was the key exposure. In-hospital mortality and length of stay, use of the intensive care unit (ICU), and ICU stay were outcome measures. Secondary data from January 2003 to October 2025 were retrieved and analysed by Poisson regression. Results: Influenza vaccine uptake among SARI-hospitalised patients dropped from about 70% in 2023 to a 40-50% level in 2024 and 2025. A single vaccine dose reduced outcomes by 10-13% compared to unvaccinated patients. Two doses per year significantly reduced mortality (32%), ICU admissions (52%), and ICU stay (28%). Conclusion: Two doses of influenza vaccine were moderately effective in decreasing in-hospital mortality and stay among SARI-hospitalised influenza patients. Including 50-59-year-olds in a priority vaccination group may significantly reduce influenza-related adverse outcomes. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability https://opendatasus.saude.gov.br/dataset/srag-2021-a-2024 Funder Information Declared Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq, Brasil , 303552/2022-0 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 21, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Protective effect of influenza vaccine in Brazilian patients hospitalised for severe acute respiratory infection, 2023-2025 Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Protective effect of influenza vaccine in Brazilian patients hospitalised for severe acute respiratory infection, 2023-2025 Emil Kupek medRxiv 2026.09.15.26362995; doi: https://doi.org/10.64898/2026.09.15.26362995 Share This Article: Copy Citation Tools Protective effect of influenza vaccine in Brazilian patients hospitalised for severe acute respiratory infection, 2023-2025 Emil Kupek medRxiv 2026.09.15.26362995; doi: https://doi.org/10.64898/2026.09.15.26362995 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Epidemiology Subject Areas All Articles Addiction Medicine (619) Allergy and Immunology (903) Anesthesia (335) Cardiovascular Medicine (4832) Dentistry and Oral Medicine (479) Dermatology (419) Emergency Medicine (651) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1633) Epidemiology (15980) Forensic Medicine (33) Gastroenterology (1206) Genetic and Genomic Medicine (7067) Geriatric Medicine (734) Health Economics (1067) Health Informatics (5060) Health Policy (1438) Health Systems and Quality Improvement (1775) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16309) Intensive Care and Critical Care Medicine (1176) Medical Education (671) Medical Ethics (155) Nephrology (727) Neurology (7294) Nursing (369) Nutrition (1084) Obstetrics and Gynecology (1244) Occupational and Environmental Health (1006) Oncology (3616) Ophthalmology (1055) Orthopedics (398) Otolaryngology (458) Pain Medicine (474) Palliative Medicine (139) Pathology (709) Pediatrics (1805) Pharmacology and Therapeutics (739) Primary Care Research (769) Psychiatry and Clinical Psychology (5921) Public and Global Health (9772) Radiology and Imaging (2433) Rehabilitation Medicine and Physical Therapy (1456) Respiratory Medicine (1250) Rheumatology (643) Sexual and Reproductive Health (773) Sports Medicine (581) Surgery (782) Toxicology (107) Transplantation (305) Urology (293)
## Related Clinical Research

- [Pennsylvania reports third measles-related death amid ongoing outbreak; other health headlines](https://medichelpline.com/clinical-feed/stat-news-2-pennsylvania-records-third-measles-related-death-amid-outbreak.md)
- [2025/26 Subclade-Specific Influenza Vaccine Effectiveness for A(H3N2), A(H1N1)pdm09, and B/Victoria](https://medichelpline.com/clinical-feed/medrxiv-11-2025-26-subclade-specific-influenza-a-and-b-vaccine-effectiveness-estimates-and.md)
- [Increased risk of acute gastroenteritis after COVID-19 hospitalisation: a retrospective England an](https://medichelpline.com/clinical-feed/medrxiv-3-risk-of-acute-gastroenteritis-following-covid-19-exposure-a-retrospective.md)
- [Medical groups, Vaccine Integrity Project issue joint RSV, Covid-19, and influenza vaccine guidanc](https://medichelpline.com/clinical-feed/stat-news-0-doctors-groups-release-vaccination-guidelines-ahead-of-respiratory-illness.md)
- [FDA approves Moderna’s mRNA flu vaccine mFLUSIVA for adults 50+: what clinicians should know](https://medichelpline.com/clinical-feed/medical-news-today-0-moderna-s-mrna-flu-vaccine-approved-by-fda-when-is-it-available.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.